

# A Study of XW003 Injection in Chinese Adolescents With Obesity

NCT07143227

---

<b>Status</b>	RECRUITING
<b>Phase</b>	Phase 1
<b>Sponsor</b>	Hangzhou Sciwind Biosciences Co., Ltd.
<b>Enrollment</b>	48 participants

## Key Eligibility Criteria

---

### Inclusion (2)

- At the time of screening, BMI meets the obesity criteria specified in WS/T586-2018 'screening for overweight and obesity among school-aged children and adolescents', and weight  $\geq 55$  kg;
- At the time of screening, the decrease of body mass index less than 5% after diet and exercise control alone for at least 12 weeks (as reported by participants or parents or legal guardians);

### Exclusion (5)

- Pre-adolescent participants (Tanner phase I);
- Obesity caused by secondary diseases or medications, including: elevated cortisol hormone (e.g. Cushing's syndrome), damage to the pituitary gland and hypothalamus, reduced dosage/discontinuation of weight-loss drugs or monogenic obesity, etc.;
- Have used any weight-loss drugs, hypoglycemic drugs, or drugs that may cause significant weight gain within 3 months prior to screening;
- Diagnosis with any type of diabetes;
- History of acute or chronic pancreatitis, history of gallbladder disease or pancreatic injury

## Locations (1 total)

---

Qilu Hospital of Shandong University, Jinan, Shandong, China